Tackling Global Challenges

Immune Targeting Systems (ITS) develops synthetic vaccines for mutating viruses underpinned by its DepoVaccine and High Density (HD) Antigen identification technology platforms. Our aim is simple - to save lives and improve the quality of life for those becoming infected by such viruses.

Latest News
Apr 16, 2013 Immune Targeting Systems announces positive Phase 2a data in the at risk elderly population with...
Sep 17, 2012 Immune Targeting Systems announces positive Phase I data for Flunisyn™, its pan-strain...
© ITS-Innovation